Liu Q, Dewi D A, Liu W, Bee M S, Schonbrunn A
Department of Integrative Biology and Pharmacology, School of Medicine, University of Texas-Houston, P.O. Box 20708, Houston, TX 77225, USA.
Mol Pharmacol. 2008 Feb;73(2):292-304. doi: 10.1124/mol.107.038570. Epub 2007 Nov 2.
The somatostatin subtype 2A (sst2A) receptor, a member of the G protein-coupled receptor superfamily, mediates many of the neuroendocrine and neuromodulatory actions of somatostatin, and it represents the primary target for somatostatin analogs used in cancer therapy and tumor localization. Agonist stimulation leads to the rapid phosphorylation, endocytosis, and desensitization of the sst2A receptor; however, little is known about the role of phosphorylation in sst2A regulation. sst2A phosphorylation occurs on serine and threonine residues in the third intracellular loop and carboxyl terminus. Therefore, we generated mutant receptors in which serine (Ser-), threonine (Thr-), or both (Ser-/Thr-) residues in these regions were mutated to alanine. In contrast to the wild-type receptor, somatostatin treatment did not stimulate the phosphorylation of the Ser-/Thr- mutant, and it did not produce desensitization. Furthermore, internalization of the Ser-/Thr- mutant occurred 5 times more slowly than with the wild-type receptor. Mutating only the Ser residues did not inhibit either internalization or desensitization. In contrast, mutating only the Thr residues inhibited receptor endocytosis to the same extent as in the full mutant, but it did not affect receptor desensitization. In both the wild-type and Ser- receptors, agonist binding produced a stable arrestin-receptor complex that was maintained during receptor trafficking, whereas arrestin was not recruited to either the Thr- or the Ser-/Thr- receptors. These results demonstrate that agonist-stimulated receptor phosphorylation is necessary for both desensitization and rapid internalization of the sst2A receptor. However, sst2A receptor internalization and uncoupling can occur independently, involve different receptor phosphorylation sites, and exhibit different requirements for stable arrestin association.
生长抑素2A亚型(sst2A)受体是G蛋白偶联受体超家族的成员,介导生长抑素的许多神经内分泌和神经调节作用,它是癌症治疗和肿瘤定位中使用的生长抑素类似物的主要靶点。激动剂刺激导致sst2A受体快速磷酸化、内吞和脱敏;然而,关于磷酸化在sst2A调节中的作用知之甚少。sst2A磷酸化发生在第三个细胞内环和羧基末端的丝氨酸和苏氨酸残基上。因此,我们生成了突变受体,其中这些区域的丝氨酸(Ser-)、苏氨酸(Thr-)或两者(Ser-/Thr-)残基被突变为丙氨酸。与野生型受体相比,生长抑素处理不会刺激Ser-/Thr-突变体的磷酸化,也不会产生脱敏作用。此外,Ser-/Thr-突变体的内化速度比野生型受体慢5倍。仅突变Ser残基既不抑制内化也不抑制脱敏。相反,仅突变Thr残基对受体内吞的抑制程度与完全突变体相同,但不影响受体脱敏。在野生型和Ser-受体中,激动剂结合都会产生稳定的抑制蛋白-受体复合物,该复合物在受体运输过程中保持稳定,而抑制蛋白不会被募集到Thr-或Ser-/Thr-受体上。这些结果表明,激动剂刺激的受体磷酸化对于sst2A受体的脱敏和快速内化都是必需的。然而,sst2A受体内化和解偶联可以独立发生,涉及不同的受体磷酸化位点,并且对稳定的抑制蛋白结合表现出不同的要求。